Evaluation of lung cancer biomarkers profile for the decision of targeted therapy in EBUS-TBNA cytological samples

Gürün Kaya A., Çiledağ A., Erol S., Öz M., Doğan Mülazımoğlu D., Işık Ö., ...Daha Fazla

SCOTTISH MEDICAL JOURNAL, cilt.67, sa.1, ss.18-27, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 67 Sayı: 1
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1177/00369330221078995
  • Dergi Adı: SCOTTISH MEDICAL JOURNAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, Food Science & Technology Abstracts, MEDLINE
  • Sayfa Sayıları: ss.18-27
  • Anahtar Kelimeler: Non-small cell lung carcinoma, lung cancer biomarker, molecular analysis, endobronchial ultrasound, targeted therapy, GROWTH-FACTOR RECEPTOR, TRANSBRONCHIAL NEEDLE ASPIRATION, MOLECULAR TESTING GUIDELINE, ENDOBRONCHIAL ULTRASOUND, INTERNATIONAL-ASSOCIATION, MUTATION ANALYSIS, DIAGNOSIS, COLLEGE, EGFR, SPECIMENS
  • Ankara Üniversitesi Adresli: Evet

Özet

Background Guidelines recommend performing biomarker tests for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF and ROS proto-oncogene-1(ROS1) genes and protein expression of programmed death ligand-1(PD-L1) in patients with non-small lung cell carcinoma (NSCLC). Studies reported that endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) can provide sufficient material for cancer biomarker analyses, but there are still concerns about the subject. Aim The purpose of the study was to assess the adequacy of EBUS-TBNA for testing lung cancer biomarkers. Methods We retrospectively reviewed patients with NSCLC whose EBUS-TBNA was analysed for EGFR, ALK, ROS-1, BRAF and PD-L1 expression between December 2011 and December 2020. Results A total of 394 patients were enrolled in the study. EGFR mutation and ALK fusion were the most common studied biomarkers. EBUS-TBNA adequacy rate for biomarker tests was found 99.0% for EGFR, 99.1 for ALK, 97.2% for ROS1, 100% for BRAF and 99.3% for PD-L1 testing. Multivariate analysis revealed the histological type, history of treatment for NSCL, size, or 18-fluorodeoxyglucose uptake of sampled lesion did not show any association with TBNA adequacy for biomarker testing. Conclusion EBUS-TBNA can provide adequate material for biomarker testing for EGFR, ALK, ROS-1, BRAF and PD-L1 expression.